YAP1 and cancer: These pathways were selected due to their well-characterized and recurrent interactions with Hippo/YAP across multiple cancer types, the abundance of high-quality studies available in recent years, and the existence of FDA-approved drugs or clinical trials exploring combination therapies involving these axes.